PLX — Protalix Biotherapeutics Income Statement
0.000.00%
Last trade - 00:00- $148.30m
- $114.90m
- $53.40m
- 55
- 56
- 39
- 49
Annual income statement for Protalix Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 62.9 | 38.4 | 47.6 | 65.5 | 53.4 |
| Cost of Revenue | |||||
| Gross Profit | 52 | 22 | 28 | 42.5 | 29.1 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 60.2 | 58.8 | 60.7 | 55 | 49.5 |
| Operating Profit | 2.71 | -20.5 | -13 | 10.5 | 3.92 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.52 | -27.6 | -14.4 | 8.57 | 4.15 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -6.52 | -27.6 | -14.9 | 8.31 | 2.93 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.52 | -27.6 | -14.9 | 8.31 | 2.93 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.52 | -27.6 | -14.9 | 8.31 | 2.93 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.224 | -0.625 | -0.308 | 0.101 | 0.036 |